These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22166919)

  • 21. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation.
    Mehravaran A; Jaafari MR; Jalali SA; Khamesipour A; Tafaghodi M; Hojatizade M; Abbasi A; Badiee A
    Iran J Immunol; 2015 Dec; 12(4):274-87. PubMed ID: 26714419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
    Soto M; Corvo L; Garde E; Ramírez L; Iniesta V; Bonay P; Gómez-Nieto C; González VM; Martín ME; Alonso C; Coelho EA; Barral A; Barral-Netto M; Iborra S
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003751. PubMed ID: 25955652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
    Santos DM; Carneiro MW; de Moura TR; Fukutani K; Clarencio J; Soto M; Espuelas S; Brodskyn C; Barral A; Barral-Netto M; de Oliveira CI
    Int J Nanomedicine; 2012; 7():2115-27. PubMed ID: 22619548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
    Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.
    Naseri H; Eskandari F; Jaafari MR; Khamesipour A; Abbasi A; Badiee A
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28921566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
    Courret N; Lang T; Milon G; Antoine JC
    Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-administration of chitin micro-particle and Leishmania antigen proposed a new immune adjuvant against experimental leishmaniasis.
    Azizi M; Yousefi R; Yeganeh F; Mami S; Haji Molla Hoseini M
    Parasite Immunol; 2019 Dec; 41(12):e12676. PubMed ID: 31593609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The levels and patterns of cytokines produced by CD4 T lymphocytes of BALB/c mice infected with Leishmania major by inoculation into the ear dermis depend on the infectiousness and size of the inoculum.
    Lang T; Courret N; Colle JH; Milon G; Antoine JC
    Infect Immun; 2003 May; 71(5):2674-83. PubMed ID: 12704142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.
    Soong L; Duboise SM; Kima P; McMahon-Pratt D
    Infect Immun; 1995 Sep; 63(9):3559-66. PubMed ID: 7642292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leishmania tropica: suggestive evidences for the effect of infectious dose on pathogenicity and immunogenicity in an experimental model.
    Rostamian M; Jafari D; Abolghazi M; Farahani H; Niknam HM
    Parasitol Res; 2018 Sep; 117(9):2949-2956. PubMed ID: 29978420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production.
    Grenfell RF; Marques-da-Silva EA; Souza-Testasicca MC; Coelho EA; Fernandes AP; Afonso LC; Rezende SA
    Mem Inst Oswaldo Cruz; 2010 Sep; 105(6):818-22. PubMed ID: 20944999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salivary gland homogenates from wild-caught sand flies Lutzomyia flaviscutellata and Lutzomyia (Psychodopygus) complexus showed inhibitory effects on Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis infection in BALB/c mice.
    Francesquini FC; Silveira FT; Passero LF; Tomokane TY; Carvalho AK; Corbett CE; Laurenti MD
    Int J Exp Pathol; 2014 Dec; 95(6):418-26. PubMed ID: 25476864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of experimental cutaneous leishmaniasis by Leishmania extract: identification of a disease-associated antibody specificity.
    Silva VM; de-Araújo CF; Navarro IC; Oliveira PR; Pontes-de-Carvalho L
    BMC Res Notes; 2015 May; 8():197. PubMed ID: 25971623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
    Ribeiro PAF; Vale DL; Dias DS; Lage DP; Mendonça DVC; Ramos FF; Carvalho LM; Carvalho AMRS; Steiner BT; Roque MC; Oliveira-da-Silva JA; Oliveira JS; Tavares GSV; Galvani NC; Martins VT; Chávez-Fumagalli MA; Roatt BM; Moreira RLF; Menezes-Souza D; Oliveira MC; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
    Cytokine; 2020 May; 129():155031. PubMed ID: 32062145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
    Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
    Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model.
    Ribeiro JG; Ferreira AS; Macedo SRA; Rossi NRDLP; da Silva MCP; Guerra RNM; de Barros NB; Nicolete R
    Int Immunopharmacol; 2017 Jun; 47():227-230. PubMed ID: 28433944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of humoral immune response to Leishmania tropica in an experimental model.
    Rostamian M; Akya A; Niknam HM
    Parasitol Res; 2019 Apr; 118(4):1231-1237. PubMed ID: 30778754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein.
    Campbell K; Popov V; Soong L
    Infect Immun; 2004 Apr; 72(4):2194-202. PubMed ID: 15039343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.